SLC5A1 and hydrops fetalis: In the SOLOIST‐WHF trial, although the trial was prematurely terminated due to COVID‐19 related impediments, dual SGLT1/2 inhibition with sotagliflozin significantly reduced risks of total cardiovascular deaths, HHF, and urgent HF visits among patients with diabetes and recent worsening HF.